References
- Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
- Richardson P, Mitsiades C, Schlossman R et al. Bortezomib in thefront-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053–1072.
- Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide anddexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995.
- Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.
- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.
- Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide—dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235–239.
- Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950.
- Richardson PG, Schlossman RL, Weller E et al. Immunomo-dulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067.
- Rajkumar SV, Hayman S, Lacy M et al. Combination therapy withlenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050–4053.
- Greipp PR, San Miguel J, Dune BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
- Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell trans-plantation. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
- Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491.
- Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043.
- Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.
- Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.
- Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and auto transplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.
- Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229–234.
- Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Eng J Med 2007; 357: 2133–2142.
- Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
- Rajkumar S, Jacobus S, Callander R et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexa-methasone as initial therapy for newly diagnosed multiple myeloma. Lancet Oncol 2010; 11: 29–37.
- Popat R, Oakervee H, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma. Br J Haematol 2008; 141: 512–516.
- Jagannath S, Dune B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.
- Lahuerta J, Mateos M, Martinez J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma. J Clin Oncol 2008; 26: 5775–5782.
- Barlogie B, Tricot G, van Rhee F et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.